

Cheng-Ta Yang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8007985/publications.pdf>

Version: 2024-02-01

158
papers

4,042
citations

126708

33
h-index

168136

53
g-index

160
all docs

160
docs citations

160
times ranked

6355
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 83-93.	1.3	2
2	A hospital cluster of COVID-19 associated with a SARS-CoV-2 superspreading event. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 436-444.	1.5	10
3	Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. <i>International Journal of Cancer</i> , 2022, 150, 626-635.	2.3	16
4	Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation. <i>Cancers</i> , 2022, 14, 316.	1.7	3
5	Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 674.	1.7	10
6	An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100292.	0.6	3
7	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI. <i>Cancers</i> , 2022, 14, 977.	1.7	12
8	The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. <i>Scientific Reports</i> , 2022, 12, 4398.	1.6	6
9	Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. <i>Thoracic Cancer</i> , 2022, 13, 1888-1897.	0.8	8
10	Nuclear p120 catenin is a component of the perichromosomal layer and coordinates sister chromatid segregation during mitosis in lung cancer cells. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	1
11	Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. <i>Journal of Clinical Oncology</i> , 2022, 40, 9035-9035.	0.8	0
12	First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110357.	1.4	12
13	Successful management of COVID-19 induced acute respiratory distress syndrome by extracorporeal membrane oxygenation with 1-year follow-up: A case report. <i>IDCases</i> , 2021, 26, e01281.	0.4	0
14	Roles of lung-recruited monocytes and pulmonary Vascular Endothelial Growth Factor (VEGF) in resolving Ventilator-Induced Lung Injury (VILI). <i>PLoS ONE</i> , 2021, 16, e0248959.	1.1	4
15	Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100131.	0.6	4
16	A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. <i>BMC Cancer</i> , 2021, 21, 309.	1.1	4
17	A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. <i>Oncology and Therapy</i> , 2021, 9, 489-503.	1.0	5
18	Relative COVID-19 Viral Persistence and Antibody Kinetics. <i>Pathogens</i> , 2021, 10, 752.	1.2	9

#	ARTICLE	IF	CITATIONS
19	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines, 2021, 9, 689.	2.1	9
20	Total Sleep Time in the Taiwan Obstructive Lung Disease Cohort. International Journal of Environmental Research and Public Health, 2021, 18, 7080.	1.2	0
21	Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer, 2021, 21, 859.	1.1	15
22	Predictors of Invasive Adenocarcinomas among Pure Ground-Glass Nodules Less Than 2 cm in Diameter. Cancers, 2021, 13, 3945.	1.7	13
23	Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study. Vaccines, 2021, 9, 1122.	2.1	18
24	Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease. Medicina (Lithuania), 2021, 57, 1160.	0.8	1
25	Infection control operations of a large hospital in Taiwan to prevent nosocomial outbreaks during COVID-19 pandemic. Biomedical Journal, 2021, 44, S8-S14.	1.4	8
26	Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells. Cell Cycle, 2020, 19, 97-108.	1.3	12
27	Concomitant infection with COVID-19 and Mycoplasma pneumoniae. Biomedical Journal, 2020, 43, 458-461.	1.4	22
28	Severe OSA associated with higher risk of mortality in stage III and IV lung cancer. Journal of Clinical Sleep Medicine, 2020, 16, 1091-1098.	1.4	27
29	Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncology, 2020, 16, 2799-2808.	1.1	50
30	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. Journal of Thoracic Oncology, 2020, 15, 1907-1918.	0.5	85
31	Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19. Thrombosis Research, 2020, 196, 11-14.	0.8	11
32	The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals, 2020, 13, 331.	1.7	14
33	The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 1361.	1.7	39
34	Circulating Tumor Cells as a Tool of Minimal Residual Disease Can Predict Lung Cancer Recurrence: A longitudinal, Prospective Trial. Diagnostics, 2020, 10, 144.	1.3	33
35	The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma. Biomedicines, 2020, 8, 36.	1.4	14
36	Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thoracic Cancer, 2020, 11, 1541-1549.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Severe Obstructive Sleep Apnea Associated With Higher Risk of Mortality in Stage III and IV Lung Cancer. <i>Journal of Clinical Sleep Medicine</i> , 2020, , .	1.4	0
38	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821.	1.8	116
39	VEGF mediates fat embolism-induced acute lung injury via VEGF receptor 2 and the MAPK cascade. <i>Scientific Reports</i> , 2019, 9, 11713.	1.6	24
40	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	1.1	71
41	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 433-440.	1.7	9
42	Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study. <i>Thoracic Cancer</i> , 2019, 10, 1683-1691.	0.8	6
43	Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. <i>Thoracic Cancer</i> , 2019, 10, 2274-2281.	0.8	4
44	Pharyngeal distensibility during expiration is an independent predictor of the severity of obstructive sleep apnoea. <i>Respirology</i> , 2019, 24, 582-589.	1.3	6
45	Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. <i>Oncology Reports</i> , 2019, 42, 697-707.	1.2	19
46	Cul4A Modulates Invasion and Metastasis of Lung Cancer through Regulation of ANXA10. <i>Cancers</i> , 2019, 11, 618.	1.7	16
47	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265.	0.5	59
48	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1158-1166.	0.8	17
49	Prognostic Value and Clinical Impact of Pretreatment FDG PET in Pulmonary Lymphoepithelioma-Like Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, e68-e75.	0.7	8
50	Monocytic C-C chemokine receptor 5 expression increases in in vitro intermittent hypoxia condition and in severe obstructive sleep apnea patients. <i>Sleep and Breathing</i> , 2019, 23, 1177-1186.	0.9	9
51	Elevated Serum Markers of Acute Kidney Injury in Patients With Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 207-213.	1.4	11
52	Prognostic impact of combining whole-body PET/CT and brain PET/MR in patients with lung adenocarcinoma and brain metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 467-477.	3.3	11
53	Downregulation of lumican accelerates lung cancer cell invasion through p120 catenin. <i>Cell Death and Disease</i> , 2018, 9, 414.	2.7	27
54	Stomatin-like protein 2 regulates survivin expression in non-small cell lung cancer cells through β -catenin signaling pathway. <i>Cell Death and Disease</i> , 2018, 9, 425.	2.7	24

#	ARTICLE	IF	CITATIONS
55	Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3139-3148.	1.6	43
56	Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3073-3085.	1.6	23
57	Accuracy of Presurgical Functional MR Imaging for Language Mapping of Brain Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2018, 286, 512-523.	3.6	46
58	Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 81-89.	1.1	29
59	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 2070-2078.	0.6	18
60	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. <i>Biomedicines</i> , 2018, 6, 114.	1.4	28
61	Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR mutant and EGFR wild type nonsquamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1648-1655.	0.8	3
62	Recurrent Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis. <i>Journal of Thoracic Oncology</i> , 2018, 13, e227-e230.	0.5	13
63	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	1.1	90
64	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 232.	2.2	10
65	Changes in and Determinants of Quality of Life in Patients With Advanced Non-Small-Cell Lung Cancer Undergoing Initial Chemotherapy. <i>The Journal of Nursing Research: JNR</i> , 2017, 25, 203-215.	0.7	14
66	Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. <i>Annals of Intensive Care</i> , 2017, 7, 9.	2.2	15
67	Dynamic driving pressure associated mortality in acute respiratory distress syndrome with extracorporeal membrane oxygenation. <i>Annals of Intensive Care</i> , 2017, 7, 12.	2.2	54
68	Coinfection and Mortality in Pneumonia-Related Acute Respiratory Distress Syndrome Patients with Bronchoalveolar Lavage. <i>Shock</i> , 2017, 47, 615-620.	1.0	21
69	Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2937-2949.	1.6	45
70	The gender difference of snore distribution and increased tendency to snore in women with menopausal syndrome: a general population study. <i>Sleep and Breathing</i> , 2017, 21, 543-547.	0.9	7
71	Predictive factors for EGFR -tyrosine kinase inhibitor retreatment in patients with EGFR -mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study. <i>Lung Cancer</i> , 2017, 104, 58-64.	0.9	22
72	Design of wearable and wireless multi-parameter monitoring system for evaluating cardiopulmonary function. <i>Medical Engineering and Physics</i> , 2017, 47, 144-150.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Design of Wearable Breathing Sound Monitoring System for Real-Time Wheeze Detection. <i>Sensors</i> , 2017, 17, 171.	2.1	83
74	The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. <i>Oncotarget</i> , 2017, 8, 97602-97612.	0.8	25
75	Feasibility of Radial Endobronchial Ultrasound-Guided Bronchoscopic Cryobiopsy without Fluoroscopy for Lung Parenchymal Lesions. <i>Canadian Respiratory Journal</i> , 2017, 2017, 1-5.	0.8	7
76	Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. <i>Oncotarget</i> , 2017, 8, 1343-1353.	0.8	36
77	Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 75952-75967.	0.8	22
78	Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. <i>Journal of Thoracic Disease</i> , 2016, 8, 1477-1486.	0.6	7
79	YAP promotes erlotinib resistance in human non-small cell lung cancer cells. <i>Oncotarget</i> , 2016, 7, 51922-51933.	0.8	94
80	Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. <i>Oncology Letters</i> , 2016, 12, 4598-4604.	0.8	49
81	Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. <i>Tumor Biology</i> , 2016, 37, 11873-11882.	0.8	4
82	A primer and probe set for detecting multiple types of EGFR exon 19 deletions. <i>Analytical Biochemistry</i> , 2016, 513, 61-67.	1.1	2
83	Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions. <i>Biomedical Journal</i> , 2016, 39, 121-129.	1.4	3
84	Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). <i>Cancer Treatment and Research Communications</i> , 2016, 9, 48-55.	0.7	7
85	Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1295-1306.	1.6	13
86	Reversibility of albuminuria and continuous positive airway pressure compliance in patients of obstructive sleep apnea syndrome. <i>Medicine (United States)</i> , 2016, 95, e4045.	0.4	12
87	TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2155-2165.	3.3	25
88	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. <i>Oncotarget</i> , 2016, 7, 53299-53308.	0.8	9
89	Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate <i>Staphylococcus aureus</i> bacteremia in patients in intensive care units. <i>BMC Infectious Diseases</i> , 2015, 15, 444.	1.3	21
90	Activation of Src-dependent Smad3 signaling mediates the neutrophilic inflammation and oxidative stress in hyperoxia-augmented ventilator-induced lung injury. <i>Respiratory Research</i> , 2015, 16, 112.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection. <i>Medicine (United States)</i> , 2015, 94, e2013.	0.4	12
92	Total Lesion Glycolysis Determined per RECIST 1.1 Criteria Predicts Survival in EGFR Mutation-Negative Patients With Advanced Lung Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e295-e299.	0.7	12
93	Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits. <i>International Journal of COPD</i> , 2015, 10, 767.	0.9	30
94	<i>Antrodia cinnamomea</i> alleviates cisplatin-induced hepatotoxicity and enhances chemo-sensitivity of line-1 lung carcinoma xenografted in BALB/cByJ mice. <i>Oncotarget</i> , 2015, 6, 25741-25754.	0.8	20
95	Gray matter atrophy in narcolepsy: An activation likelihood estimation meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 59, 53-63.	2.9	27
96	Diffuse alveolar damage associated mortality in selected acute respiratory distress syndrome patients with open lung biopsy. <i>Critical Care</i> , 2015, 19, 228.	2.5	87
97	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. <i>Journal of Thoracic Oncology</i> , 2015, 10, 793-799.	0.5	199
98	Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. <i>Oncology Reports</i> , 2015, 34, 3187-3195.	1.2	13
99	Survival Predictors in Acute Respiratory Distress Syndrome With Extracorporeal Membrane Oxygenation. <i>Annals of Thoracic Surgery</i> , 2015, 99, 243-250.	0.7	42
100	Immediate and Long-term Neurocognitive Outcome in Patients with Obstructive Sleep Apnea Syndrome After Continuous Positive Airway Pressure Treatment. <i>Indian Journal of Otolaryngology and Head and Neck Surgery</i> , 2015, 67, 79-85.	0.3	6
101	The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old in Taiwan's PPV vaccination program. <i>Vaccine</i> , 2015, 33, 2897-2902.	1.7	51
102	Cytoplasmic and nuclear parathyroid hormone-related proteins are opposing prognostic factors in patients with non-small-cell lung cancer who have undergone curative resection. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 267-273.	0.6	5
103	Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 90, 472-476.	0.9	14
104	Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2015, 113, 1519-1528.	2.9	94
105	The impact of aerosolized mucolytic agents on the airflow resistance of bacterial filters used in mechanical ventilation. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 717-721.	0.8	1
106	Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer. <i>Biomedical Journal</i> , 2015, 38, 329.	1.4	5
107	Circulating Endothelial-Derived Activated Microparticle: A Useful Biomarker for Predicting One-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer. <i>BioMed Research International</i> , 2014, 1-11.	0.9	37
108	Chronic Obstructive Pulmonary Disease in Stage I Non-small Cell Lung Cancer That Underwent Anatomic Resection: The Role of a Recurrence Promoter. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 407-413.	0.7	19

#	ARTICLE	IF	CITATIONS
109	Mechanical ventilation augments bleomycin-induced epithelialâ€mesenchymal transition through the Src pathway. <i>Laboratory Investigation</i> , 2014, 94, 1017-1029.	1.7	14
110	Overall Response to First-Line Tyrosine Kinase Inhibitor and Second-Line Chemotherapy Is Predictive of Survival Outcome in Epidermal Growth Factor Receptor-Mutated Adenocarcinoma. <i>Chemotherapy</i> , 2014, 60, 201-210.	0.8	4
111	Mapping Gray Matter Reductions in Obstructive Sleep Apnea: An Activation Likelihood Estimation Meta-Analysis. <i>Sleep</i> , 2014, 37, 167-175.	0.6	84
112	Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e107160.	1.1	11
113	The utility of surgical lung biopsy in cancer patients with acute respiratory distress syndrome. <i>Journal of Cardiothoracic Surgery</i> , 2013, 8, 128.	0.4	2
114	MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. <i>Virology Journal</i> , 2013, 10, 241.	1.4	42
115	Improvement of ventilator-induced lung injury by IPS cell-derived conditioned medium via inhibition of PI3K/Akt pathway and IP-10-dependent paracrine regulation. <i>Biomaterials</i> , 2013, 34, 78-91.	5.7	40
116	Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. <i>International Journal of Oncology</i> , 2013, 43, 1517-1522.	1.4	18
117	Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value. <i>Disease Markers</i> , 2013, 35, 301-310.	0.6	48
118	Lumican Regulates Ventilation-Induced Epithelial-Mesenchymal Transition Through Extracellular Signal-Regulated Kinase Pathway. <i>Chest</i> , 2013, 143, 1252-1260.	0.4	26
119	Suppressing NF-Î²B and NKRF Pathways by Induced Pluripotent Stem Cell Therapy in Mice with Ventilator-Induced Lung Injury. <i>PLoS ONE</i> , 2013, 8, e66760.	1.1	18
120	Diseases in Patients Coming to a Sleep Center with Symptoms Related to Restless Legs Syndrome. <i>PLoS ONE</i> , 2013, 8, e71499.	1.1	13
121	Ethyl pyruvate reduces ventilation-induced neutrophil infiltration and oxidative stress. <i>Experimental Biology and Medicine</i> , 2012, 237, 720-727.	1.1	14
122	High-Frequency Oscillatory Ventilation for Rescue From Refractory Hypoxemia in a Patient With Transfusion-Related Acute Lung Injury. <i>Respiratory Care</i> , 2012, 57, 798-801.	0.8	2
123	Effects of cardiac output levels on the measurement of transpulmonary thermodilution cardiac output in patients with acute respiratory distress syndrome. <i>Journal of Trauma and Acute Care Surgery</i> , 2012, 73, 1236-1241.	1.1	3
124	Invasive fungal infection among hematopoietic stem cell transplantation patients with mechanical ventilation in the intensive care unit. <i>BMC Infectious Diseases</i> , 2012, 12, 44.	1.3	6
125	Hydroxyethyl starch reduces high stretch ventilation-augmented lung injury via vascular endothelial growth factor. <i>Translational Research</i> , 2011, 157, 293-305.	2.2	20
126	Lumican Expression in Diaphragm Induced by Mechanical Ventilation. <i>PLoS ONE</i> , 2011, 6, e24692.	1.1	7

#	ARTICLE	IF	CITATIONS
127	Resolution of Organ Functional Scores to Predict the Outcome in Adult Acute Respiratory Distress Syndrome Patients Receiving High-Frequency Oscillatory Ventilation. <i>Journal of Trauma</i> , 2011, 71, 1536-1542.	2.3	3
128	Cul4A is an oncogene in malignant pleural mesothelioma. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 350-358.	1.6	61
129	Renal replacement therapy in prolonged mechanical ventilation patients with renal failure in Taiwan. <i>Journal of Critical Care</i> , 2011, 26, 600-607.	1.0	12
130	CK2 Inhibitors Enhance the Radiosensitivity of Human Non-Small Cell Lung Cancer Cells Through Inhibition of Stat3 Activation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 381-388.	0.7	23
131	Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor site. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 115-123.	1.2	34
132	Low-molecular-weight heparin reduces hyperoxia-augmented ventilator-induced lung injury via serine/threonine kinase-protein kinase B. <i>Respiratory Research</i> , 2011, 12, 90.	1.4	29
133	Obstructive sleep apnea: a stand-alone risk factor for chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2244-2250.	0.4	103
134	Transcriptional regulation of the ORF61 and ORF60 genes of Kaposi's sarcoma-associated herpesvirus. <i>Virology</i> , 2010, 397, 311-321.	1.1	17
135	The prevalence of restless legs syndrome in Taiwanese adults. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 170-178.	1.0	70
136	Functional Polymorphism of the CK2± Intronless Gene Plays Oncogenic Roles in Lung Cancer. <i>PLoS ONE</i> , 2010, 5, e11418.	1.1	31
137	Gefitinib as First-line Therapy for Advanced or Metastatic Non-small Cell Lung Cancer Patients in Southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2010, 26, 1-7.	0.8	0
138	Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. <i>BMC Cancer</i> , 2009, 9, 135.	1.1	26
139	WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 919-924.	1.2	30
140	Inhibition of corneal neovascularization with plasmid pigment epithelium-derived factor (p-PEDF) delivered by synthetic amphiphile INTERaction-18 (SAINT-18) vector in an experimental model of rat corneal angiogenesis. <i>Experimental Eye Research</i> , 2009, 89, 678-685.	1.2	22
141	Pulmonary cryptococcosis: Clinical, radiographical and serological markers of dissemination. <i>Respirology</i> , 2008, 13, 247-251.	1.3	28
142	A Novel Vector System for Gene Transfer into the Cornea Using a Partially Dried Plasmid Expressing 18 Basic Fibroblast Growth Factor±Synthetic Amphiphile INTERaction-18 (SAINT-18) Complex. <i>Current Eye Research</i> , 2008, 33, 839-848.	0.7	4
143	Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. <i>Nature Precedings</i> , 2008, , .	0.1	0
144	Wnt Inhibitory Factor-1 Gene Transfer Inhibits Melanoma Cell Growth. <i>Human Gene Therapy</i> , 2007, 18, 379-386.	1.4	49

#	ARTICLE	IF	CITATIONS
145	Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 635-640.	1.0	63
146	The sensitivity of human mesenchymal stem cells to ionizing radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 244-253.	0.4	163
147	p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1461-1472.	0.4	19
148	Acute Pyelonephritis Associated with Transudative Pleural Effusion in a Middle-Aged Woman without Urinary Tract Obstruction. <i>Medical Principles and Practice</i> , 2006, 15, 309-311.	1.1	6
149	Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo. <i>BMC Cancer</i> , 2005, 5, 158.	1.1	44
150	Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells. <i>Anticancer Research</i> , 2005, 25, 2049-54.	0.5	20
151	Early Referral as an Independent Predictor of Clinical Outcome in End-Stage Renal Disease on Hemodialysis and Continuous Ambulatory Peritoneal Dialysis. <i>Renal Failure</i> , 2004, 26, 531-537.	0.8	27
152	Improved Anemia and Reduced Erythropoietin Need by Medical or Surgical Intervention of Secondary Hyperparathyroidism in Hemodialysis Patients. <i>Renal Failure</i> , 2004, 26, 289-295.	0.8	32
153	Most Common Intoxication in Nephrology Ward Organophosphate Poisoning. <i>Renal Failure</i> , 2004, 26, 349-354.	0.8	18
154	LV Mass Index Significantly Impacts on Patient and Renal Outcomes in Patients with Coronary Artery Bypass Grafting and Poor Left-Ventricular Function. <i>Renal Failure</i> , 2003, 25, 287-295.	0.8	5
155	A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and) Tj ETQq1 1 0.784314 rgBJ /Overl	0.5	20
156	Adenovirus-Mediated p14ARF Gene Transfer in Human Mesothelioma Cells. <i>Journal of the National Cancer Institute</i> , 2000, 92, 636-641.	3.0	120
157	Tuberculin purified protein derivative up-regulates the telomerase activity of peripheral blood mononuclear cells from patients with pulmonary tuberculosis. <i>Life Sciences</i> , 1999, 64, 1383-1391.	2.0	4
158	Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. <i>Respiratory Medicine</i> , 1995, 89, 121-128.	1.3	32